These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 26910079)
1. Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model. Braga S Methods Mol Biol; 2016; 1395():251-80. PubMed ID: 26910079 [TBL] [Abstract][Full Text] [Related]
3. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523 [TBL] [Abstract][Full Text] [Related]
5. A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer. Zdenkowski N; Butow P; Mann GB; Fewster S; Beckmore C; Isaacs R; Douglas C; Boyle FM Intern Med J; 2016 Jun; 46(6):677-83. PubMed ID: 26929045 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy for breast cancer. Liu SV; Melstrom L; Yao K; Russell CA; Sener SF J Surg Oncol; 2010 Mar; 101(4):283-91. PubMed ID: 20187061 [TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
8. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
9. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer. Hyun SH; Ahn HK; Park YH; Im YH; Kil WH; Lee JE; Nam SJ; Cho EY; Choi JY Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075 [TBL] [Abstract][Full Text] [Related]
10. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Goble S; Bear HD Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542 [TBL] [Abstract][Full Text] [Related]
12. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404 [TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769 [TBL] [Abstract][Full Text] [Related]
14. Primary systemic therapy of breast cancer. Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Tan QX; Qin QH; Yang WP; Mo QG; Wei CY Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769 [TBL] [Abstract][Full Text] [Related]
17. Current and future role of neoadjuvant therapy for breast cancer. Untch M; Konecny GE; Paepke S; von Minckwitz G Breast; 2014 Oct; 23(5):526-37. PubMed ID: 25034931 [TBL] [Abstract][Full Text] [Related]
18. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279 [TBL] [Abstract][Full Text] [Related]
19. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. Viale G Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800 [TBL] [Abstract][Full Text] [Related]
20. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Kim R; Osaki A; Toge T Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]